
Fluoropolymers at a Crossroads: A Possible Ban that Shocks the Industry
Fluoropolymers at a Crossroads: A Possible Ban that Shocks the Industry
Fluoropolymers at a Crossroads: A Possible Ban that Shocks the Industry
The amendment of Regulation (EU) 2023/607 opens up new opportunities for those transitioning their medical devices to the MDR. Legacy devices can now have the validity of their directive certificates extended (until the end of 2027/2028, depending on the device classification) if certain conditions are met.
Foundation for the National Institutes of Health (FNIH) Announces AMP BGTC’s Selection of Eight Rare Diseases for Clinical Trials, Paving the Way for Streamlined Gene
Promotion of Authentic Healthcare Innovations and Treatments
Rare Disease Treatment: Exciting Advances in Clinical Research
Unlocking the Power of the 5HT-2A Receptor: Natural Ways to Enhance Mood and Cognition for Optimal Brain Function
The Future of Life Science Research: Targeted Solutions and Collaborative Expertise with REAgency+
CTIS Submission Planning and Implementation Expert at REAgency+ Available to Offer Support and Solutions
Experienced Clinical Research Partner: REAgency+ Facilitates Biotech Industry Advancements and Product Introductions
REA Research Experts Alliance GmbH & Co. KG
Schönhauser Allee 163
10435 Berlin, Germany
Tel.: 030-52 105 151
E-Mail: success@researchexpertsalliance.agency